Copyright © 2010 IUPHAR
Annotated and expert reviewed. Please contact us if you can help with updates.
α1A-adrenoceptor
Previous and Unofficial Names  |
| α1a |
| α1c |
| adrenergic receptor |
Structural Information  |
|
class A G protein-coupled receptor |
| Species |
TM |
AA |
Chromosomal Location |
Gene Name |
Reference |
| Human |
7 |
466 |
8p21-p11.2 |
ADRA1A
|
|
| Rat |
7 |
466 |
15p12 |
Adra1a
|
|
| Mouse |
7 |
466 |
14 D1 |
Adra1a
|
|
|
|
Database Links  |
|
ChEMBL Target |
125 (Hs), 12271 (Mm), 12514 (Rn) |
|
Ensembl |
ENSG00000120907 (Hs), ENSMUSG00000045875 (Mm), ENSRNOG00000009522 (Rn) |
|
Entrez Gene |
148 (Hs), 11549 (Mm), 29412 (Rn) |
|
GeneCards |
ADRA1A (Hs) |
|
HomoloGene |
68078 (Hs) |
|
OMIM |
104221 (Hs) |
|
PharmGKB Gene |
PA34 (Hs) |
|
Protein Ontology (PRO) |
PRO:000001183 (Hs) |
|
RefSeq Nucleotide |
NM_000680 (Hs), NM_013461 (Mm), NM_017191 (Rn) |
|
RefSeq Protein |
NP_000671 (Hs), NP_038489 (Mm), NP_058887 (Rn) |
|
UniGene Hs. |
52931 (Hs) |
|
UniProt |
P35348 (Hs), P97718 (Mm), P43140 (Rn) |
|
Wikipedia |
α1A-adrenoceptor |
| Search for 3D structures on the PDB |
|
Search using keywords: Adrenoceptors alpha1A-adrenoceptor
|
Search using accession numbers: P43140 || P35348 || P97718
|
| Antagonists |
|
Key to terms and symbols
|
View all chemical structures |
Click column headers to sort
|
| Ligand |
|
|
|
|
|
[125I]BE-2254
|
|
|
|
|
Hs |
Antagonist |
9.9 |
pKd |
5,29 |
|
(-)-YM617
|
|
|
|
|
Hs |
Antagonist |
10.7 |
pKi |
17 |
|
KMD-3213
|
|
|
|
|
Hs |
Antagonist |
10.4 |
pKi |
17 |
|
tamsulosin
|
|
|
|
|
Hs |
Antagonist |
10.0 – 10.4 |
pKi |
4,23,27-28 |
|
WB 4101
|
|
|
|
|
Rn |
Antagonist |
10.2 |
pKi |
22 |
|
NAN 190
|
|
|
|
|
Hs |
Antagonist |
10.1 |
pKi |
25 |
|
WB 4101
|
|
|
|
|
Hs |
Antagonist |
9.7 – 9.8 |
pKi |
4,17,23,28 |
|
Rec 15/2739
|
|
|
|
|
Hs |
Antagonist |
9.6 |
pKi |
4 |
|
RS-100329
|
|
|
|
|
Hs |
Antagonist |
9.6 |
pKi |
27 |
|
(+)-niguldipine
|
|
|
|
|
Hs |
Antagonist |
9.1 – 9.9 |
pKi |
4,17 |
|
prazosin
|
|
|
|
|
Rn |
Inverse agonist |
9.5 |
pKi |
22 |
|
prazosin
|
|
|
|
|
Hs |
Inverse agonist |
9.0 – 9.9 |
pKi |
4,17,23,27-28 |
|
(+)-niguldipine
|
|
|
|
|
Rn |
Antagonist |
9.3 |
pKi |
22 |
|
RS-17053
|
|
|
|
|
Hs |
Antagonist |
9.2 – 9.3 |
pKi |
4,23,28 |
|
5-methylurapidil
|
|
|
|
|
Hs |
Antagonist |
8.9 – 9.2 |
pKi |
4,17,23-25 |
|
5-methylurapidil
|
|
|
|
|
Rn |
Antagonist |
9.0 |
pKi |
22 |
|
Ro-70-0004
|
|
|
|
|
Hs |
Antagonist |
8.9 |
pKi |
27 |
|
SNAP5089
|
|
|
|
|
Hs |
Antagonist |
8.8 |
pKi |
3 |
|
A-119637
|
|
|
|
|
Hs |
Antagonist |
8.6 |
pKi |
26 |
|
A-119637
|
|
|
|
|
Rn |
Antagonist |
8.6 |
pKi |
26 |
|
phentolamine
|
|
|
|
|
Hs |
Antagonist |
8.6 |
pKi |
17 |
|
roxindole
|
|
|
|
|
Hs |
Antagonist |
8.6 |
pKi |
1 |
|
A-123189
|
|
|
|
|
Rn |
Antagonist |
8.5 |
pKi |
26 |
|
terguride
|
|
|
|
|
Hs |
Antagonist |
8.5 |
pKi |
1 |
|
A-123189
|
|
|
|
|
Hs |
Antagonist |
8.4 |
pKi |
26 |
|
indoramin
|
|
|
|
|
Hs |
Antagonist |
8.4 |
pKi |
4,28 |
|
risperidone
|
|
|
|
|
Hs |
Antagonist |
8.4 |
pKi |
25 |
|
ritanserin
|
|
|
|
|
Hs |
Antagonist |
8.4 |
pKi |
25 |
|
lisuride
|
|
|
|
|
Hs |
Antagonist |
8.3 |
pKi |
1 |
|
spiperone
|
|
|
|
|
Hs |
Antagonist |
8.3 |
pKi |
25 |
|
ketanserin
|
|
|
|
|
Hs |
Antagonist |
8.2 |
pKi |
25 |
|
clozapine
|
|
|
|
|
Hs |
Antagonist |
8.1 |
pKi |
25 |
|
phentolamine
|
|
|
|
|
Rn |
Antagonist |
8.1 |
pKi |
22 |
|
(+)-cyclazosin
|
|
|
|
|
Hs |
Antagonist |
7.9 |
pKi |
21 |
|
mianserin
|
|
|
|
|
Hs |
Antagonist |
7.6 |
pKi |
25 |
|
cyproheptadine
|
|
|
|
|
Hs |
Antagonist |
7.4 |
pKi |
25 |
|
spiroxatrine
|
|
|
|
|
Hs |
Antagonist |
7.3 |
pKi |
25 |
|
BMY-7378
|
|
|
|
|
Rn |
Antagonist |
7.0 |
pKi |
26 |
|
BMY-7378
|
|
|
|
|
Hs |
Antagonist |
6.9 – 7.0 |
pKi |
25-26 |
|
cabergoline
|
|
|
|
|
Hs |
Antagonist |
6.5 |
pKi |
1 |
|
piribedil
|
|
|
|
|
Hs |
Antagonist |
6.1 |
pKi |
1 |
|
|
View species-specific antagonist tables
|
| Antagonist Comments |
Compounds such as prazosin and RS-17053 show unexpectedly low potency in certain isolated tissue assays (e.g. canine prostate) [3]. This was postulated to result from a novel α1- adrenoceptor subtype (α1L). It is now thought that this may result from differences in α1A-adrenoceptor characteristics dependent on tissue or assay environment [4].
Compounds designated as "partial inverse agonists" [5] are listed as neutral antagonists |
| Allosteric Regulator Comments |
| While no allosteric regulation of the α1A-adrenoceptor has been proven, possible allosteric enhancement has been shown with high concentrations of benzodiazepines. Amiloride analogs will increase the dissociation rate of prazosin from the α1A- adrenoceptor [2] |
Primary Transduction Mechanisms
|
| Transducer |
Effector/Response |
|
Gq/G11 family |
Phospholipase C stimulation Calcium channel Other - See Comments |
Secondary Transduction Mechanisms  |
| Transducer |
Effector/Response |
|
|
Phospholipase D stimulation Other - See Comments |
Tissue Distribution
|
| In the human brain, the highest levels of α1A message are found in olfactory system, hypothalamic nuclei and in regions of the brainstem and spinal cord related to motor function. |
| Species: |
Human |
| Technique: |
in situ hybridisation. |
| References: |
9 |
|
|
| High expression levels of α1A-adrenoceptor mRNA are found in the heart, liver, cerebelum and cerebral cortex |
| Species: |
Human |
| Technique: |
RNase Protection |
| References: |
10 |
|
|
| The α1A-adrenoceptor is the predominant subtype in human prostate and urethra. |
| Species: |
Human |
| Technique: |
Immunohistochemistry. |
| References: |
11 |
|
|
Functional Assays
|
| Isolated longitudinal strip of Vas Deferens. |
| Species: |
Rat |
| Tissue: |
Vas deferens |
| Response measured: |
Contraction |
| References: |
8 |
|
|
| Isolated strips of prostate tissue containing both glandular and smooth muscle elements. |
| Species: |
Human |
| Tissue: |
Prostrate |
| Response measured: |
Contraction |
| References: |
4 |
|
|
Physiological Functions
|
| Contraction of stromal and capsular smooth muscle to control urethral resistance. |
| Species: |
Human |
| Tissue: |
Prostate. |
| References: |
13 |
|
|
| Contraction of urethral smooth muscle. |
| Species: |
Human |
| Tissue: |
Urethra. |
| References: |
14 |
|
|
| Stimulation of myocyte hypertrophy. |
| Species: |
Rat |
| Tissue: |
Myocardium. |
| References: |
15 |
|
|
| Activation of sarcolemmal Na+-H+ exchanger. |
| Species: |
Rat |
| Tissue: |
Ventricular Myocytes. |
| References: |
16 |
|
|
| Contraction of skeletal muscle resistance arteries. |
| Species: |
Human |
| Tissue: |
Vasculature. |
| References: |
12 |
|
|
Physiological Consequences of Altering Gene Expression
|
| Cardiac specific overexpression of α1A-adrenoceptors enhanced cardiac contractility. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Transgenesis. |
| References: |
6 |
|
|
| Hypotension and a decreased pressor response to phenylephrine were observed in α1A- knockout mice. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Transgenesis. |
| References: |
7 |
|
|
To cite this receptor data page, please use the following:
Richard A. Bond, David B. Bylund, Douglas C. Eikenburg, J. Paul Hieble, Rebecca Hills, Kenneth P. Minneman, Sergio Parra.
Adrenoceptors: α1A-adrenoceptor. Last modified on 2010-06-28. Accessed on 2010-09-03. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=22.
Contact us | Print | Back to top | Help